Protocol 3: Comprehensive approach (advanced, with medical supervision) Goal: Full-spectrum immune modulation with organ support Phase 1 (Weeks 1-4): Foundation Thymosin alpha-1: 1.6 mg subcutaneously, three times weekly BPC-157: 300 mcg subcutaneously, twice daily Phase 2 (Weeks 5-12): Add modulation Continue Phase 1 peptides Add KPV: 300-500 mcg subcutaneously, once daily Add Selank: 500 mcg intranasally, once daily Phase 3 (Weeks 13-16): Organ support cycle Continue Phase 2 peptides Add Thymalin: 10 mg course over 10 days Add targeted bioregulators based on affected organs (kidney, cardiac, vascular as needed) Phase 4 (Weeks 17-20): Rest and assess Discontinue all peptides Monitor disease activity markers Assess sustained benefits Plan next cycle based on results Monitoring: Full labs every 4 weeks, including CBC, CMP, complement levels, anti-dsDNA, CRP, ESR, urine protein/creatinine ratio
Stack Rationale: The combination may offer complementary mechanismssystemic repair signaling (TB-500) plus localized tissue healing (BPC-157)
Administration and Guidance AOD-9604 is administered via subcutaneous injection, typically in the abdominal area
Administration Route by Peptide Type When Injectable GHK-CU Makes Sense The injectable form provides systemic benefits that topical cannot achieve: Whole-body tissue regeneration effects Internal organ support Consistent blood levels Better bioavailability Combined with other injectable peptides When Topical Makes Sense Topical application excels for: Targeted skin treatment Hair and scalp applications Those avoiding injections Combination with skincare routines Localized wound healing For maximum benefit, some protocols use both injectable GHK-CU for systemic effects and topical copper peptides for targeted skin benefits
[17] References [edit] "NCAA Drug-Testing Program | 2023-24" (PDF)
Vitamin injections fortify this barrier, making the skin more resilient against external damage
